Treatment of skin tumors with intratumoral interleukin 12 gene electrotransfer in the head and neck region: a first-in-human clinical trial protocol

1Fares CM, van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S. Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients? Am Soc Clin Oncol Educ Book 2019; 39: 147-64. doi: 10.1200/EDBK_240837Fares CM van Allen EM Drake CG Allison JP Hu-Lieskovan S Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients? Am Soc Clin Oncol Educ Book 2019 39 147 64 10.1200/EDBK_24083731099674Open DOISearch in Google Scholar

2Nguyen KG, Vrabel MR, Mantooth SM, Hopkins JJ, Wagner ES, Gabaldon TA, et al. Localized interleukin-12 for cancer immunotherapy. Front Immunol 2020; 11: 575597. doi: 10.3389/fimmu.2020.575597Nguyen KG Vrabel MR Mantooth SM Hopkins JJ Wagner ES Gabaldon TA et al Localized interleukin-12 for cancer immunotherapy Front Immunol 2020 11 575597 10.3389/fimmu.2020.575597759376833178203Open DOISearch in Google Scholar

3Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, et al. Effects of single-dose interleukin-12 exposure on interleukin-12–associated toxicity and interferon-γ production. Blood 1997; 90: 2541-8. doi: 10.3389/fimmu.2020.575597Leonard JP Sherman ML Fisher GL Buchanan LJ Larsen G Atkins MB et al Effects of single-dose interleukin-12 exposure on interleukin-12–associated toxicity and interferon-γ production Blood 1997 90 2541 8 10.3389/fimmu.2020.575597Open DOISearch in Google Scholar

4Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008; 26: 5896-903. doi:10.1200/JCO.2007.15.6794Daud AI DeConti RC Andrews S Urbas P Riker AI Sondak VK et al Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma J Clin Oncol 2008 26 5896 903 10.1200/JCO.2007.15.6794264511119029422Open DOISearch in Google Scholar

5Spanggaard I, Snoj M, Cavalcanti A, Bouquet C, Sersa G, Robert C, et al. Gene electrotransfer of plasmid antiangiogenic metargidin peptide (AMEP) in disseminated melanoma: safety and efficacy results of a phase i first-in-man study. Hum Gene Ther Clin Dev 2013; 24: 99-107. doi: 10.1089/humc.2012.240Spanggaard I Snoj M Cavalcanti A Bouquet C Sersa G Robert C et al Gene electrotransfer of plasmid antiangiogenic metargidin peptide (AMEP) in disseminated melanoma: safety and efficacy results of a phase i first-in-man study Hum Gene Ther Clin Dev 2013 24 99 107 10.1089/humc.2012.24023980876Open DOISearch in Google Scholar

6Yarmush ML, Golberg A, Serša G, Kotnik T, Miklavčič D. Electroporation-based technologies for medicine: principles, applications, and challenges. Annu Rev Biomed Eng 2014; 16: 295-320. doi: 10.1146/ANNUREV-BIOENG-071813-104622Yarmush ML Golberg A Serša G Kotnik T Miklavčič D Electroporation-based technologies for medicine: principles, applications, and challenges Annu Rev Biomed Eng 2014 16 295 320 10.1146/ANNUREV-BIOENG-071813-104622Open DOISearch in Google Scholar

7Rosazza C, Haberl Meglic S, Zumbusch A, Rols M-P, Miklavcic D. Gene electrotransfer: a mechanistic perspective. Curr Gene Ther 2016; 16: 98-129. doi: 0.2174/1566523216666160331130040Rosazza C Haberl Meglic S Zumbusch A Rols M-P Miklavcic D Gene electrotransfer: a mechanistic perspective Curr Gene Ther 2016 16 98 129 0.2174/156652321666616033113004010.2174/1566523216666160331130040541200227029943Search in Google Scholar

8Canton DA, Shirley S, Wright J, Connolly R, Burkart C, Mukhopadhyay A, et al. Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid). Immunother 2017; 9: 1309-21. doi: 10.2217/imt-2017-0096Canton DA Shirley S Wright J Connolly R Burkart C Mukhopadhyay A et al Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid) Immunother 2017 9 1309 21 10.2217/imt-2017-009629064334Open DOISearch in Google Scholar

9Bhatia S, Longino N V., Miller NJ, Kulikauskas R, Iyer JG, Ibrani D, et al. Intratumoral delivery of plasmid IL12 via electroporation leads to regression of injected and noninjected tumors in Merkel cell carcinoma. Clin Cancer Res 2020; 26: 598-607. doi: 10.1158/1078-0432.CCR-19-0972Bhatia S Longino N V. Miller NJ Kulikauskas R Iyer JG Ibrani D et al Intratumoral delivery of plasmid IL12 via electroporation leads to regression of injected and noninjected tumors in Merkel cell carcinoma Clin Cancer Res 2020 26 598 607 10.1158/1078-0432.CCR-19-0972986800431582519Open DOISearch in Google Scholar

10Cemazar M, Jarm T, Sersa G. Cancer electrogene therapy with interleukin-12. Curr Gene Ther 2010; 10: 300-11. doi: 10.2174/156652310791823425Cemazar M Jarm T Sersa G Cancer electrogene therapy with interleukin-12 Curr Gene Ther 2010 10 300 11 10.2174/15665231079182342520560875Open DOISearch in Google Scholar

11Telli ML, Nagata H, Wapnir I, Acharya CR, Zablotsky K, Fox BA, et al. Intratumoral plasmid IL12 expands CD8 + T cells and induces a CXCR3 gene signature in triple-negative breast tumors that sensitizes patients to anti-PD-1 therapy. Clin Cancer Res 2021; 27: 2481-93. doi: 10.1158/1078-0432.CCR-20-3944Telli ML Nagata H Wapnir I Acharya CR Zablotsky K Fox BA et al Intratumoral plasmid IL12 expands CD8 + T cells and induces a CXCR3 gene signature in triple-negative breast tumors that sensitizes patients to anti-PD-1 therapy Clin Cancer Res 2021 27 2481 93 10.1158/1078-0432.CCR-20-3944810233133593880Open DOISearch in Google Scholar

12Greaney SK, Algazi AP, Tsai KK, Takamura KT, Chen L, Twitty CG, et al. Intratumoral plasmid IL12 electroporation therapy in patients with advanced melanoma induces systemic and intratumoral T-cell responses. Cancer Immunol Res 2020; 8: 246-54. doi: 10.1158/2326-6066.CIR-19-0359Greaney SK Algazi AP Tsai KK Takamura KT Chen L Twitty CG et al Intratumoral plasmid IL12 electroporation therapy in patients with advanced melanoma induces systemic and intratumoral T-cell responses Cancer Immunol Res 2020 8 246 54 10.1158/2326-6066.CIR-19-0359700223231852717Open DOISearch in Google Scholar

13Algazi AP, Twitty CG, Tsai KK, Le M, Pierce R, Browning E, et al. Phase II trial of IL-12 plasmid transfection and PD-1 blockade in immunologically quiescent melanoma. Clin Cancer Res 2020; 26: 2827-37. doi: 10.1158/1078-0432.CCR-19-2217Algazi AP Twitty CG Tsai KK Le M Pierce R Browning E et al Phase II trial of IL-12 plasmid transfection and PD-1 blockade in immunologically quiescent melanoma Clin Cancer Res 2020 26 2827 37 10.1158/1078-0432.CCR-19-2217935465332376655Open DOISearch in Google Scholar

14Dollin Y, Rubin J, Carvajal RD, Rached H, Nitzkorski JR. Pembrolizumab and tavokinogene telseplasmid electroporation in metastatic melanoma. Int J Surg Case Rep 2020; 77: 591-4. doi: 10.1016/J.IJSCR.2020.11.063Dollin Y Rubin J Carvajal RD Rached H Nitzkorski JR Pembrolizumab and tavokinogene telseplasmid electroporation in metastatic melanoma Int J Surg Case Rep 2020 77 591 4 10.1016/J.IJSCR.2020.11.063770875433395852Open DOISearch in Google Scholar

15Kos S, Bosnjak M, Jesenko T, Markelc B, Kamensek U, Znidar K, et al. Non-clinical in vitro evaluation of antibiotic resistance gene-free plasmids encoding human or murine IL-12 intended for first-in-human clinical study. Pharmaceutics 2021; 13: 1739. doi: 10.3390/PHARMACEUTICS13101739Kos S Bosnjak M Jesenko T Markelc B Kamensek U Znidar K et al Non-clinical in vitro evaluation of antibiotic resistance gene-free plasmids encoding human or murine IL-12 intended for first-in-human clinical study Pharmaceutics 2021 13 1739 10.3390/PHARMACEUTICS13101739Open DOISearch in Google Scholar

16Kamensek U, Tesic N, Sersa G, Cemazar M. Clinically usable interleukin 12 plasmid without an antibiotic resistance gene: functionality and toxicity study in murine melanoma model. Cancers 2018; 10: 60. doi: 10.3390/cancers10030060Kamensek U Tesic N Sersa G Cemazar M Clinically usable interleukin 12 plasmid without an antibiotic resistance gene: functionality and toxicity study in murine melanoma model Cancers 2018 10 60 10.3390/cancers10030060587663529495490Open DOISearch in Google Scholar

17Clover AJP, Salwa SP, Bourke MG, McKiernan J, Forde PF, O’Sullivan ST, et al. Electrochemotherapy for the treatment of primary basal cell carcinoma; A randomised control trial comparing electrochemotherapy and surgery with five year follow up. Eur J Surg Oncol 2020; 46: 847-54. doi: 10.1016/J.EJSO.2019.11.509Clover AJP Salwa SP Bourke MG McKiernan J Forde PF O’Sullivan ST et al Electrochemotherapy for the treatment of primary basal cell carcinoma; A randomised control trial comparing electrochemotherapy and surgery with five year follow up Eur J Surg Oncol 2020 46 847 54 10.1016/J.EJSO.2019.11.50931862134Open DOISearch in Google Scholar

18Stratigos AJ, Sekulic A, Peris K, Bechter O, Prey S, Kaatz M, et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol 2021; 22: 848-57. doi: 10.1016/S1470-2045(21)00126-1Stratigos AJ Sekulic A Peris K Bechter O Prey S Kaatz M et al Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial Lancet Oncol 2021 22 848 57 10.1016/S1470-2045(21)00126-134000246Open DOISearch in Google Scholar

19Jayaraman SS, Rayhan DJ, Hazany S, Kolodney MS. Mutational landscape of basal cell carcinomas by whole-exome sequencing. J Invest Dermatol 2014; 134: 213.20. doi: 10.1038/JID.2013.276Jayaraman SS Rayhan DJ Hazany S Kolodney MS Mutational landscape of basal cell carcinomas by whole-exome sequencing J Invest Dermatol 2014 134 213 20 10.1038/JID.2013.276Open DOISearch in Google Scholar

20Clover AJP, de Terlizzi F, Bertino G, Curatolo P, Odili J, Campana LG, et al. Electrochemotherapy in the treatment of cutaneous malignancy: outcomes and subgroup analysis from the cumulative results from the pan-European International Network for Sharing Practice in Electrochemotherapy database for 2482 lesions in 987 patients (2008-2019). Eur J Cancer 2020; 138: 30-40. doi: 10.1016/J.EJCA.2020.06.020Clover AJP de Terlizzi F Bertino G Curatolo P Odili J Campana LG et al Electrochemotherapy in the treatment of cutaneous malignancy: outcomes and subgroup analysis from the cumulative results from the pan-European International Network for Sharing Practice in Electrochemotherapy database for 2482 lesions in 987 patients (2008-2019) Eur J Cancer 2020 138 30 40 10.1016/J.EJCA.2020.06.020Open DOISearch in Google Scholar

21Bertino G, Sersa G, De Terlizzi F, Occhini A, Plaschke CC, Groselj A, et al. European research on electrochemotherapy in head and neck cancer (EURECA) project: results of the treatment of skin cancer. Eur J Cancer 2016; 63: 41-52. doi: 10.1016/J.EJCA.2016.05.001Bertino G Sersa G De Terlizzi F Occhini A Plaschke CC Groselj A et al European research on electrochemotherapy in head and neck cancer (EURECA) project: results of the treatment of skin cancer Eur J Cancer 2016 63 41 52 10.1016/J.EJCA.2016.05.001Open DOISearch in Google Scholar

22Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348: 124-8. doi: 10.1126/SCIENCE.AAA1348Rizvi NA Hellmann MD Snyder A Kvistborg P Makarov V Havel JJ et al Cancer immunology mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015 348 124 8 10.1126/SCIENCE.AAA1348Open DOISearch in Google Scholar

23Sykes AJ, Wlodek C, Trickey A, Clayton GL, Oakley A. Growth rate of clinically diagnosed superficial basal cell carcinoma and changes in dermoscopic features over time. Australas J Dermatol 2020; 61: 330-6. doi: 10.1111/AJD.13352Sykes AJ Wlodek C Trickey A Clayton GL Oakley A Growth rate of clinically diagnosed superficial basal cell carcinoma and changes in dermoscopic features over time Australas J Dermatol 2020 61 330 6 10.1111/AJD.1335232578200Open DOISearch in Google Scholar

24Gehl J, Sersa G, Matthiessen LW, Muir T, Soden D, Occhini A, et al. Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases. Acta Oncol 2018; 57: 874-82. doi: 10.1080/0284186X.2018.1454602Gehl J Sersa G Matthiessen LW Muir T Soden D Occhini A et al Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases Acta Oncol 2018 57 874 82 10.1080/0284186X.2018.145460229577784Open DOISearch in Google Scholar

25Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76. doi: 10.1093/JNCI/85.5.365Aaronson NK Ahmedzai S Bergman B Bullinger M Cull A Duez NJ et al The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 1993 85 365 76 10.1093/JNCI/85.5.3658433390Open DOISearch in Google Scholar

26Ahčan U, Bertenjev I, Benedičič A, Bremec T, Dugonik A, Grošelj A, et al. Recommendations for diagnosis, treatment and follow-up of patients with basal cell carcinoma. Onkologija 2019; 23: 74-94. doi: 10.25670/oi2019-008onAhčan U Bertenjev I Benedičič A Bremec T Dugonik A Grošelj A et al Recommendations for diagnosis, treatment and follow-up of patients with basal cell carcinoma Onkologija 2019 23 74 94 10.25670/oi2019-008onOpen DOISearch in Google Scholar

27European Medicines Agency; EMEA/CHMP/GTWP/60436/2007. Guideline on Follow-up of Patients Administered with Gene Therapy Medical Products. London; 2009; 1-12. [cited 2022 Feb 15]. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-follow-patients-administered-gene-therapy-medicinal-products_en.pdfEuropean Medicines Agency; EMEA/CHMP/GTWP/60436/2007 Guideline on Follow-up of Patients Administered with Gene Therapy Medical Products London 2009 1–12 [cited 2022 Feb 15]. Available at https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-follow-patients-administered-gene-therapy-medicinal-products_en.pdfSearch in Google Scholar

28Algazi A, Bhatia S, Agarwala S, Molina M, Lewis K, Faries M, et al. Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. Ann Oncol 2020; 31: 532-40. doi: 10.1016/j.annonc.2019.12.008Algazi A Bhatia S Agarwala S Molina M Lewis K Faries M et al Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients Ann Oncol 2020 31 532 40 10.1016/j.annonc.2019.12.00832147213Open DOISearch in Google Scholar

29Vandermeulen G, Marie C, Scherman D, Préat V. New generation of plasmid backbones devoid of antibiotic resistance marker for gene therapy trials. Mol Ther 2011; 19: 1942-9. doi: 10.1038/MT.2011.182Vandermeulen G Marie C Scherman D Préat V New generation of plasmid backbones devoid of antibiotic resistance marker for gene therapy trials Mol Ther 2011 19 1942 9 10.1038/MT.2011.182322253321878901Open DOISearch in Google Scholar

30Vanpouille-Box C, Pilones KA, Wennerberg E, Formenti SC, Demaria S. In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine 2015; 33: 7415-22. doi: 10.1016/j.vaccine.2015.05.105Vanpouille-Box C Pilones KA Wennerberg E Formenti SC Demaria S In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment Vaccine 2015 33 7415 22 10.1016/j.vaccine.2015.05.105468448026148880Open DOISearch in Google Scholar

31Sersa G, Teissie J, Cemazar M, Signori E, Kamensek U, Marshall G, et al. Electrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransfer. Cancer Immunol Immunother 2015; 64: 1315-27. doi: 10.1007/S00262-015-1724-2Sersa G Teissie J Cemazar M Signori E Kamensek U Marshall G et al Electrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransfer Cancer Immunol Immunother 2015 64 1315 27 10.1007/S00262-015-1724-2Open DOISearch in Google Scholar

32Campana LG, Peric B, Mascherini M, Spina R, Kunte C, Kis E, et al. Combination of pembrolizumab with electrochemotherapy in cutaneous metastases from melanoma: a comparative retrospective study from the InspECT and Slovenian Cancer Registry. Cancers 2021; 13: 4289. doi:10.3390/cancers13174289Campana LG Peric B Mascherini M Spina R Kunte C Kis E et al Combination of pembrolizumab with electrochemotherapy in cutaneous metastases from melanoma: a comparative retrospective study from the InspECT and Slovenian Cancer Registry Cancers 2021 13 4289 10.3390/cancers13174289842833534503099Open DOISearch in Google Scholar

33Buchwald ZS, Wynne J, Nasti TH, Zhu S, Mourad WF, Yan W, et al. Radiation, immune checkpoint blockade and the abscopal effect: a critical review on timing, dose and fractionation. Front Oncol 2018; 8: 612. doi: 10.3389/fonc.2018.00612Buchwald ZS Wynne J Nasti TH Zhu S Mourad WF Yan W et al Radiation, immune checkpoint blockade and the abscopal effect: a critical review on timing, dose and fractionation Front Oncol 2018 8 612 10.3389/fonc.2018.00612630603430619752Open DOISearch in Google Scholar

34Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 2013; 1: 365-72. doi: 10.1158/2326-6066.CIR-13-0115Golden EB Demaria S Schiff PB Chachoua A Formenti SC An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer Cancer Immunol Res 2013 1 365 72 10.1158/2326-6066.CIR-13-0115393045824563870Open DOISearch in Google Scholar

35Formenti SC, Rudqvist NP, Golden E, Cooper B, Wennerberg E, Lhuillier C, et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med 2018; 24: 1845-51. doi: 10.1038/s41591-018-0232-2Formenti SC Rudqvist NP Golden E Cooper B Wennerberg E Lhuillier C et al Radiotherapy induces responses of lung cancer to CTLA-4 blockade Nat Med 2018 24 1845 51 10.1038/s41591-018-0232-2628624230397353Open DOISearch in Google Scholar

36Plavc G, Jesenko T, Oražem M, Strojan P. Challenges in combining immunotherapy with radiotherapy in recurrent/metastatic head and neck cancer. Cancers 2020; 12: 1-25. doi: 10.3390/cancers12113197Plavc G Jesenko T Oražem M Strojan P Challenges in combining immunotherapy with radiotherapy in recurrent/metastatic head and neck cancer Cancers 2020 12 1 25 10.3390/cancers12113197769212033143094Open DOISearch in Google Scholar